When used strategically, peptide protocols may help support optimization across multiple areas of health and performance
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
In search of weight loss drugs, without the high prices or FDA oversight Around 2023, GLP-1 knock-offs entered the mainstream via regulated, US-based compounding pharmacies
(just one cause of B12 deficiency) and I remember that by then I was a walking "Zombie"